Latest Intelligence on Pharmaceuticals in Asia-Pacific

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

AAN 2010: late-stage pipeline candidates take center stage in migraine

In the wake of Imitrex's and Topamax's patent expiries, announcements at this year's American Academy of Neurology meeting focused firmly on the next major breakthroughs for the acute and prophylactic migraine markets. Pooled data for candidates from Allergan and Merck & Co demonstrated impressive potential, suggesting renewed hope for sufferers.

Published By Datamonitor
20 Apr 2010
Expert View
Expert View

AAN 2010: new treatments address unmet needs in Alzheimer's and epilepsy

A number of leading drug makers used this year's meeting of the American Academy of Neurology to present new data for promising pipeline candidates. Despite promising results, however, Datamonitor believes that the epilepsy drugs will struggle to find their place in the market. Moreover, the positive Phase II data for Baxter's potential Alzheimer's therapy Gammagard do not guarantee later success.

Published By Datamonitor
20 Apr 2010
Expert View
Expert View

AAN 2010: spotlight shines on Novartis' and Merck KGaA's oral MS candidates

Datamonitor attended this year's American Academy of Neurology conference, where developments in multiple sclerosis took precedence for the third consecutive year. Both Novartis and Merck KGaA presented new data for their pipeline candidates, while Acorda used the meeting as a platform to share data for its symptomatic treatment Ampyra, which was recently approved by the FDA.

Published By Datamonitor
20 Apr 2010
Expert View
Expert View

AAN 2012: BG-12 remains main focus of Biogen's extensive MS portfolio

Biogen used the platform of the 64th American Academy of Neurology Annual Meeting to provide updates on its extensive MS portfolio. Much time was devoted to its Phase III pipeline candidate BG-12, which looks set to be the next agent to enter the market, as well as the presentation of long-term safety data for Tysabri.

Published By Datamonitor
03 May 2012
Expert View
Expert View

AAN 2012: Novartis presents new data in an attempt to boost confidence in long-term use of Gilenya

In keeping with American Academy of Neurology meetings of recent years, multiple sclerosis once again dominated proceedings at AAN 2012. Novartis used the platform to present new data from the extension FREEDOMS II trial to support the long-term use of Gilenya, and provided Phase II results for siponimod in relapse remitting multiple sclerosis.

Published By Datamonitor
03 May 2012
Expert View
Expert View

AAN 2012: pooled data support future use of late-stage MS and epilepsy products

Teva, Eisai, and GlaxoSmithKline all used the opportunity of this year's American Academy of Neurology Annual Meeting to showcase pooled analysis of their late-stage pipeline candidates. While not groundbreaking, the positive data for laquinimod (MS) and perampanel and Potiga (epilepsy) will bolster physician confidence and position the drugs well in their respective markets.

Published By Datamonitor
03 May 2012
Expert View
Expert View

AAN 2012: research shows value of early disease identification, but caution in treatment is advised

At AAN 2012, Merck Serono presented data from a long-term study showing that early Rebif treatment significantly reduced the clinical progression of multiple sclerosis. However, early intervention should be used cautiously to avoid unnecessary treatment.

Published By Datamonitor
03 May 2012
CommentWire
CommentWire

Abbott: 3,000 jobs axed as synergies with Solvay are realized

Following the acquisition of Solvay, Abbott Laboratories plans to lay-off 3,000 global workers. The job cuts are part of Abbott's drive to achieve long-term goals and improve efficiencies, while at the same time increasing sales and per-share earnings. The company's broader strategy is to increase access to emerging markets and diversify its products in the hope of increasing industry growth.

Published By Datamonitor
22 Sep 2010
CommentWire
CommentWire

Abbott: safeguarding market leadership through elagolix deal

Global healthcare firm Abbott has boosted its gonadotropin releasing hormones pipeline through a deal with Neurocrine for the continued development of new promising candidate elagolix. The partnership is favorable for both parties, with Abbott seeking to maintain its endometriosis market leadership after Lupron's patent expiry in 2014.

Published By Datamonitor
17 Jun 2010
Expert View
Expert View

ACR 2009: Benlysta outshines disappointing rheumatoid arthritis data

Datamonitor recently attended this year's American College of Rheumatology Annual Conference in Philadelphia. No ground-breaking data for rheumatoid arthritis therapies were presented; instead, systemic lupus erythematosus stole the limelight. Human Genome Sciences' Benlysta in particular generated a stir, being the first drug in this indication to generate positive data at Phase III.

Published By Datamonitor
23 Oct 2009

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.